Over the Counter CBD Products Help Dispel Outdated Stigmas – PRNewswire

NEW YORK, March 16, 2021 /PRNewswire/ — Due to recent regulatory changes, the cannabis industry is slowly evolving out of the black market and morphing into a global economic powerhouse. As such, the CBD market is much more attractive in the U.S. because of the passage of the Farm Bill in late 2018. The bill legalized hemp-derived CBD products as long as they contained 0.3% THC or less. Consequently, CBD products began to rapidly emerge in retailers across the country. Even though both hemp and marijuana belong to the cannabis family, the major difference between the two is that CBD does not stimulate psychotropic effects, while THC does indeed cause mind-altering effects. Now, as a result of this understanding, more countries have become keen to approve CBD as a medical treatment solution. HempFusion Wellness Inc. (TSX: CBD.U) (OTC: CBDHF), Tilray, Inc. (NASDAQ: TLRY), Aurora Cannabis Inc. (NYSE: ACB), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Trulieve Cannabis Corp. (OTC: TCNNF) (CSE: TRUL) 

Currently, the medical cannabis sector accounts for the majority of the market share. Additionally, progress is slowly being made in removing the stigmas associated with such products. Medical cannabis is predominantly being used to alleviate symptoms associated with afflictions such as chronic pain, cancer, and epilepsy. Positive data has even led many U.S. states to legalize medical cannabis, as CBD products, in particular, have become more popular and well-known due to their lack of psychoactive effects many associate with cannabis. For example, in a survey conducted by HelloMD and Brightfield Group, approximately 60% out of 2,400 patients said that CBD participants used the compound to successfully treat insomnia or other sleep problems. Meanwhile, 42% of CBD users stopped using traditional medications and now use cannabis instead, and 80% of CBD users found CBD to be very or extremely effective for treatment.

HempFusion Wellness Inc. (TSX: CBD.U) (OTC: CBDHF) announced last week, „that its OTC Topical Products have ranked number one in both sales dollars and units sold at a major Food & Drug Mass („FDM”) retailer according to a recent NielsenIQ share report.

’Ranking #1 across all measured data, including #1 in sales by dollar volume and #1 by SKU volume, is a tremendous honor. Consumers are validating our team’s mission of providing best in class products that adhere to the highest standards of regulatory compliance,' commented Jason Mitchell, N.D., the Company’s Co-Founder and Chief Executive Officer. 'Since its inception in 2015, HempFusion’s goal has been to develop and provide consumers with the highest quality products on the market, without compromise. We are meticulous in sourcing the right raw materials, ingredients, and delivery methods to help consumers live a more balanced lifestyle, and the FDM channel provides us with an unprecedented distribution opportunity to help us reach those consumers,' continued Dr. Mitchell.

The FDM channel represents the largest sales opportunity for the Company’s products by dollar volume. According to Brightfield Group, in Q3, 2020, 41% of CBD consumers reported they recently started shopping in-store again for products that contain CBD; and CBD specialty retailers and pharmacies saw an uptick in consumer-reported purchasing. HempFusion looks forward to leveraging this initial FDM channel success with other major retailers across the United States and abroad.

’The Food & Drug Mass channel has been a significant focal point of HempFusion’s strategic distribution plan, and to see our products quickly become the top-selling CBD brand according to NielsonIQ, in this entire Top 5 FDM Grocery retail chain, is incredibly exciting,' commented Jon Visser, the Company’s Chief Revenue Officer. 'This third-party data demonstrates that our overall strategy of producing premium products with a focus on regulatory compliance, consumer messaging, and the right price point is resonating very well with category shoppers. We believe this is just the beginning. We are in continued talks with other top FDM retailers both domestically and internationally to ensure this data is widely available,' continued Visser.”

For our latest „Buzz on the Street” Show featuring HempFusion Wellness Inc., recent corporate news, please head over to: https://www.youtube.com/watch?v=v5dunIPyP70

Tilray, Inc. (NASDAQ: TLRY) announced last week that it has received the necessary approvals from New Zealand’s Ministry of Health and the Medicinal Cannabis Agency to launch Tilray medical cannabis products across the country. Tilray is one of the leading providers of medical cannabis in Australia and New Zealand for commercial, compassionate access, and research purposes and the first Licensed Producer to legally export medical cannabis from North America to Australia and New Zealand from its Good Manufacturing Practices (GMP)-certified facility in Canada. Brendan Kennedy, Tilray’s Chief Executive Officer, said, „As medical cannabis regulations continue to progress around the world, we’re incredibly honored to be recognized as a trusted partner in offering the highest-quality medical cannabis products. We are grateful to partner with New Zealand’s Ministry of Health and the Medicinal Cannabis Agency to improve access for patients in need across the country.”

Aurora Cannabis Inc. (NYSE: ACB) reported earlier this year that it has entered into a strategic agreement with MedReleaf Australia („MedReleaf”). The companies have signed a five-year supply agreement, which provides for MedReleaf to act as the exclusive supplier in Australia of Aurora’s MedReleaf, CanniMed and Aurora brands. Products covered by the agreement will be EUGMP certified and include dried flower, oils, and soft gels, as well as future products employing new delivery mechanisms. The agreement does not require or include any capital investment by Aurora.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced last year that the Company was recognized by the Toronto Stock Exchange as the third top-performing company on the Toronto Stock Exchange’s 2020 TSX30 list, a flagship program recognizing the 30 top-performing TSX stocks over a three-year period based on dividend-adjusted share price appreciation. „Cronos Group’s recognition by the TSX30 initiative is a welcomed acknowledgment of all the hard work we have put into building Cronos Group over the past three years,” said Mike Gorenstein, Executive Chairman, Cronos Group. „We’re looking forward to continuing to build and create long-term value for our shareholders by focusing our efforts on R&D, innovation and creating quality products.” Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents.

Trulieve Cannabis Corp. (OTCQX: TCNNF) (CSE: TRUL) announced last week that it has partnered with Morehouse School of Medicine to fund and conduct medical cannabis research and education. Trulieve and the Morehouse School of Medicine have entered into a mutually agreeable collaborative research, education, and development agreement where Trulieve Georgia will support Morehouse School of Medicine medical cannabis-related research and development projects, and provide course education opportunities and resources. Among the first of its kind in the United States and as one of Trulieve’s core long-term objectives, this partnership will represent one of the initial steps toward the development of personalized medical cannabis treatment.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For hempfusion wellness inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:

[email protected]

SOURCE FinancialBuzz.com

Dodaj komentarz